In this section
@article{Yalchin:2019:10.1177/1756284819891038,
author = {Yalchin, M and Segal, JP and Mullish, BH and Quraishi, MN and Iqbal, TH and Marchesi, JR and Hart, AL},
doi = {10.1177/1756284819891038},
journal = {Therapeutic Advances in Gastroenterology},
title = {Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease},
url = {http://dx.doi.org/10.1177/1756284819891038},
volume = {12},
year = {2019}
}
TY - JOUR
AB - <jats:p> Faecal microbiota transplant (FMT) has now been established into clinical guidelines for the treatment of recurrent and refractory Clostridioides difficile infection (CDI). Its therapeutic application in inflammatory bowel disease (IBD) is currently at an early stage. To date, there have been four randomized controlled trials for FMT in IBD and a multitude of observational studies. However, significant gaps in our knowledge regarding optimum methods for FMT preparation, technical aspects and logistics of its administration, as well as mechanistic underpinnings, still remain. In this article, we aim to highlight these gaps by reviewing evidence and making key recommendations on the direction of future studies in this field. In addition, we provide an overview of the current evidence of potential mechanisms of FMT in treating IBD. </jats:p>
AU - Yalchin,M
AU - Segal,JP
AU - Mullish,BH
AU - Quraishi,MN
AU - Iqbal,TH
AU - Marchesi,JR
AU - Hart,AL
DO - 10.1177/1756284819891038
PY - 2019///
SN - 1756-2848
TI - Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease
T2 - Therapeutic Advances in Gastroenterology
UR - http://dx.doi.org/10.1177/1756284819891038
UR - http://hdl.handle.net/10044/1/74876
VL - 12
ER -
For any enquiries about the Microbiome Network at Imperial, please contact: